Article
Potential Utility of PPARγ Agonists in the Eradication of Chronic Myeloid Leukemia Stem Cells
2025-08-06
Abstract excerpt
<title>Abstract</title> <p> Tyrosine kinase inhibitors (TKIs) have transformed the treatment of chronic myeloid leukemia (CML), yet persistent leukemia stem cells (LSCs) remain a barrier to cure. PPARγ agonists like pioglitazone have been proposed to enhance eradication of LSCs when used alongside TKIs. This study investigated the impact of adding pioglitazone to imatinib therapy in 26 newly diagnosed chronic-ph...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- edadc08d-6541-555c-9c83-f30fe3914ac6
- DOI
- 10.21203/rs.3.rs-7140724/v1
